Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Kinome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Kinome. Displaying page 1 of 1.
    EudraCT Number: 2015-002855-85 Sponsor Protocol Number: HO135 Start Date*: 2016-03-18
    Sponsor Name:HOVON Foundation
    Full Title: A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (...
    Medical condition: Acute Meyloid Leukemia and High Risk Myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) LT (Prohibited by CA)
    Trial results: View results
    EudraCT Number: 2010-019982-27 Sponsor Protocol Number: ABR-32011 Start Date*: 2010-07-15
    Sponsor Name:VU medical center
    Full Title: Targeted therapy selection based on tumor tissue kinase activity profiles for patients with advanced solid malignancies, an exploratory study
    Medical condition: Advanced (metastasized or inoperable) solid cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000551-41 Sponsor Protocol Number: IMPACT_Breast_6.3 Start Date*: 2014-03-18
    Sponsor Name:University Medical Center Groningen
    Full Title: Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion – Metastatic Breast Cancer
    Medical condition: Metastatic Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000154-19 Sponsor Protocol Number: UC-0105/1701 Start Date*: 2017-07-19
    Sponsor Name:UNICANCER
    Full Title: A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer
    Medical condition: PIK3CA mutated, HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001652-36 Sponsor Protocol Number: UC-0105/1304 Start Date*: 2014-01-17
    Sponsor Name:UNICANCER
    Full Title: Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer
    Medical condition: Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001653-27 Sponsor Protocol Number: UC_0105-1305_/_IFCT_1301 Start Date*: 2014-07-24
    Sponsor Name:UNICANCER
    Full Title: Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic non small cell lung cancer
    Medical condition: Patients with metastatic non small cell lung cancer (NSCLC) in 1st line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Nov 03 22:35:06 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA